Cefepime is another type of antibiotic medicine. It's used to treat serious infections caused by bacteria. It's particularly good at fighting infections in the abdomen, urinary tract, lungs, and skin. It's often used for more serious infections or when other antibiotics might not work. It's usually given through an IV line.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Cefepime is an injectable antibiotic used to treat serious bacterial infections, usually in the hospital, although some people finish a course at home through an IV line. It belongs to the cephalosporins, a large family of antibiotics related to penicillin, and it works against a broad range of bacteria. In the US, cefepime is approved for moderate to severe pneumonia, bladder and kidney infections (including pyelonephritis, an infection that has reached the kidney), uncomplicated skin infections, and, in adults, complicated infections inside the abdomen, where it is paired with metronidazole, an antibiotic that covers bacteria cefepime misses. Children from 2 months of age can receive it for most of these uses. It is also a standard first treatment for fever in people whose infection-fighting white blood cells are very low, a situation called febrile neutropenia that often follows chemotherapy. Because infections can move fast when these cells are scarce, the antibiotic is started before the exact germ is known. For people at especially high risk, such as after a recent bone marrow transplant or with low blood pressure, cefepime alone may not be enough and other medicines are added. Doctors often reach for cefepime because it works against Pseudomonas aeruginosa, a hard-to-treat bacterium common in hospital infections. Like all antibiotics, it does nothing against viruses such as colds or flu. It was once sold under the brand name Maxipime, which is no longer on the US market; today it is given as a generic. A separate product, Zaynich, combines cefepime with a second ingredient called zidebactam and was approved in the US in 2026 for complicated urinary tract infections in adults.
Bacteria are wrapped in a cell wall, a rigid outer layer that holds them together. Cefepime latches onto the proteins bacteria use to build that wall, so the wall cannot be completed and the bacteria break apart and die. Human cells have no cell wall, which is why the drug can target bacteria without attacking the body's own tissue in the same way. Not every bacterium is vulnerable. Some make enzymes, called beta-lactamases, that break down cefepime and related antibiotics, or have other defenses. That is why the care team sends samples of blood, urine or other fluids for culture, a lab test that identifies the bacteria and shows which antibiotics work against them, and may change the antibiotic once results arrive. In Zaynich, zidebactam blocks some of these bacterial enzymes, helping cefepime work against certain resistant bacteria that cause urinary infections.
Cefepime is given into a vein (intravenously, or IV) as an infusion that usually runs over about 30 minutes, typically every 8 or 12 hours. It comes either as a powder that is mixed with liquid just before use or as a premixed bag. It can also be injected into a muscle, but only for milder urinary tract infections caused by E. coli. A course commonly lasts 7 to 10 days, depending on the infection; for fever with a low white blood cell count, it may continue until the counts recover. Children receive a dose based on their weight. The kidneys clear cefepime from the body, so the dose is lowered or the doses are spaced further apart when kidney function is reduced, including for people on dialysis. This adjustment matters for safety, because cefepime that builds up in the blood can affect the brain. The care team estimates kidney function from blood tests and may change the dose if kidney function shifts during an illness. People who continue treatment at home are taught how to give the infusions or are visited by a home infusion nurse. If a home dose is missed, give it when remembered unless the next one is nearly due, and never double up to catch up.
Most people tolerate cefepime well. The most common problems are pain, redness or swelling where the IV enters the vein, and rash. At higher doses, diarrhea, nausea, vomiting, itching, fever and headache become somewhat more frequent. Routine blood tests during treatment may show small changes in liver tests or other values, which the care team follows. Uncommonly, cefepime affects the brain. Signs include new confusion, hallucinations, unusual drowsiness, trouble speaking, muscle twitching or jerking, and seizures, including seizures that show up only as reduced alertness rather than shaking. This happens mostly in people with reduced kidney function whose dose was not lowered enough, though it can occur with appropriate dosing. It usually clears after cefepime is stopped, sometimes with dialysis to remove the drug. Any of these changes should be reported to the nurse or care team right away; relatives visiting someone in the hospital are often the first to notice them. At home, a seizure or being impossible to wake calls for 911. Like other antibiotics, cefepime can let Clostridioides difficile (C. diff), a bacterium that causes severe diarrhea and inflammation of the colon, overgrow in the gut. Watery or bloody diarrhea, stomach cramps or fever during treatment or up to two months afterward should be reported to the care team promptly. Serious allergic reactions are rare. Trouble breathing or swallowing, or swelling of the throat or tongue, needs immediate help: in the hospital, alert staff at once; at home, stop the infusion and call 911. A new rash or itching should be reported to the care team.
Cefepime is not given to people who have had an immediate allergic reaction, such as hives, swelling or anaphylaxis (a severe whole-body allergic reaction), to cefepime, another cephalosporin, a penicillin or a related antibiotic. Other kinds of past reactions to penicillin call for caution, because some people react to both. Describing exactly what happened, and when, helps the team decide whether cefepime is safe. The kidneys are checked more closely when cefepime is combined with aminoglycosides, another group of IV antibiotics such as gentamicin, or with strong diuretics (water pills) such as furosemide, because these combinations can strain the kidneys. It also helps to tell the team about any history of seizures, colitis or other bowel disease, or kidney or liver disease. Cephalosporins, including cefepime, can lower the blood's clotting ability in some people, mainly those with kidney or liver disease, poor nutrition or a long course of treatment. The team may check clotting tests and give vitamin K if needed. For people with diabetes who test their urine for sugar, some older tablet-type tests can give falsely high results during treatment; enzyme-based test strips are not affected. Cefepime itself has not been studied in pregnancy, but decades of experience with cephalosporins have not shown a link to birth defects or miscarriage. Small amounts pass into breast milk, so anyone breastfeeding should mention it to the team.
Most people begin to feel better within the first few days. Cefepime is often started before the cause of an infection is confirmed, so once culture results come back the team may continue it, switch to an antibiotic aimed more narrowly at the bacteria found, or change course if the bacteria are resistant. Fever or other symptoms that persist or worsen after a few days are a reason for the team to reassess. During treatment, expect regular blood tests to check kidney function and blood counts, especially when kidney function is changing or the course is long. The full course matters even after symptoms improve: stopping early or skipping doses can leave the infection incompletely treated and encourage resistant bacteria. If signs of infection remain after the last dose, contact the doctor. Because C. diff diarrhea can appear weeks after an antibiotic ends, new watery diarrhea in the following two months is still worth reporting.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Cefepime, what you've noticed, or ask the community a question.